Moore Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Moore Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-25,000	Closed	-$792K	–	860
2021 Q1	$792K	Sell	25,000 -25,000	-50%	-$1.04M	0.01%	523
2020 Q4	$2.32M	Sell	50,000 -169,982	-77%	-$6.75M	0.03%	342
2020 Q3	$7.24M	Buy	219,982 +169,982	+340%	+$5.21M	0.14%	141
2020 Q2	$1.37M	Buy	50,000 +25,000	+100%	+$822K	0.04%	202
2020 Q1	$748K	Sell	25,000 -111,040	-82%	-$2.94M	0.03%	138
2019 Q4	$3.77M	Buy	136,040 +12,441	+10%	+$283K	0.12%	158
2019 Q3	$2.25M	Buy	123,599 +48,599	+65%	+$1.07M	0.09%	204
2019 Q2	$1.84M	Sell	75,000 -75,000	-50%	-$1.13M	0.04%	233
2019 Q1	$1.43M	Hold	150,000	–	–	0.04%	218
2018 Q4	$1.33M	Buy	150,000 +25,000	+20%	+$241K	0.05%	166
2018 Q3	$1.41M	Buy	125,000 +75,000	+150%	+$1.06M	0.03%	206
2018 Q2	$640K	Buy	+50,000	New	+$731K	0.02%	225

Other funds holding IOVA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Moore Capital Management's IOVA Position: Q2 2021 in Review

Moore Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2021, closing a stake of 25,000 shares — an estimated $792K sold.

Moore Capital Management first reported a position in IOVA in Q2 2018 and held it in 12 quarters. The position peaked at $7.24M in Q3 2020. 234 funds tracked by Wall St. Rank hold IOVA as of Q2 2021.

Moore Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2021 after selling out during the quarter.
Moore Capital Management sold 25,000 Iovance Biotherapeutics shares in Q2 2021, an estimated $792K.
Moore Capital Management first reported a position in Iovance Biotherapeutics in Q2 2018 and held it in 12 quarters.
Moore Capital Management's Iovance Biotherapeutics position peaked at $7.24M in Q3 2020.
234 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2021.

Based on Moore Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.